Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection

Inclusion Criteria: * Diagnosis of ABSSSI (wound infections, cellulitis/erysipelas, or cutaneous abscess) suspected or confirmed to be caused by a Gram-positive pathogen requiring IV therapy * Able to give informed consent and willing to comply with all required study procedures Exclusion Criteria: * Infections associated with, or in close proximity to, a prosthetic device * Severe sepsis or refractory shock * Known or suspected bacteremia at time of screening * ABSSSI due to or associated with any of the following: * Infections suspected or documented to be caused by Gram-negative pathogens (i.e., human or animal bites, injuries contaminated with fresh or salt water, external malignant otitis) * Wound infections (surgical or traumatic) and abscesses with only Gram-negative pathogens * Diabetic foot infections (infection extending distal to the malleoli in a participant with diabetes mellitus and peripheral neuropathy and/or vascular insufficiency or any ulceration of their foot) * Concomitant infection at another site not including a secondary ABSSSI lesion (e.g., septic arthritis, endocarditis, osteomyelitis) * Infected burns * A primary infection secondary to a pre-existing skin disease with associated inflammatory changes such as atopic dermatitis, eczema, or hidradenitis suppurativa * Decubitus or chronic skin ulcer, or ischemic ulcer due to peripheral vascular disease (arterial or venous) * Any evolving necrotizing process (i.e., necrotizing fasciiti…